There is currently considerable interest in the development of medicines that would enhance endocannabinoid-induced "autoprotection", for example through inhibition of endocannabinoid metabolizing enzymes or cellular uptake processes or that would oppose endocannabinoid-induced "autoimpairment". This volume describes the physiology, pathophysiology and pharmacology of the endocannabinoid system and potential strategies for targeting this system in the clinic.

Endocannabinoids and their pharmacological actions. Biosynthesis and fate of endocannabinoids. Distribution of the endocannabinoid system. Endocannabinoids and neurotransmission in health and disease. Endocannabinoids and the immune system in health and disease. Genetic manipulation of the endocannabinoid system and some consequences of this. Modulators of endocannabinoid biosynthesis, metabolism and cellular uptake as potential medicines. Endocannabinoids and mental disorders. Endocannabinoids and neurodegenerative disorders. Endocannabinoids in multiple sclerosis and amyotrophic lateral sclerosis. Endocannabinoids and metabolic disorders. Endocannabinoids and the cardiovascular system in heath and disease. Endocannabinoids and the digestive tract and bladder in health and disease. Endocannabinoids and the endocrine system in health and disease. Endocannabinoids and the reproductive system in health and disease. Endocannabinoids and cell viability/cancer.